MASI
Price
$167.57
Change
-$3.77 (-2.20%)
Updated
Jul 3 closing price
Capitalization
7.66B
38 days until earnings call
PACB
Price
$1.60
Change
+$0.11 (+7.38%)
Updated
Jul 3 closing price
Capitalization
976.68M
25 days until earnings call
Interact to see
Advertisement

MASI vs PACB

Header iconMASI vs PACB Comparison
Open Charts MASI vs PACBBanner chart's image
Masimo
Price$167.57
Change-$3.77 (-2.20%)
Volume$498.67K
Capitalization7.66B
Pacific Biosciences of California
Price$1.60
Change+$0.11 (+7.38%)
Volume$13.77M
Capitalization976.68M
MASI vs PACB Comparison Chart in %
Loading...
MASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MASI vs. PACB commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MASI is a Hold and PACB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (MASI: $167.57 vs. PACB: $1.60)
Brand notoriety: MASI and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MASI: 78% vs. PACB: 145%
Market capitalization -- MASI: $7.66B vs. PACB: $976.68M
MASI [@Medical Specialties] is valued at $7.66B. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MASI’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • MASI’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, MASI is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MASI’s TA Score shows that 6 TA indicator(s) are bullish while PACB’s TA Score has 6 bullish TA indicator(s).

  • MASI’s TA Score: 6 bullish, 4 bearish.
  • PACB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MASI is a better buy in the short-term than PACB.

Price Growth

MASI (@Medical Specialties) experienced а +0.52% price change this week, while PACB (@Medical Specialties) price change was +24.03% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.93%. For the same industry, the average monthly price growth was +1.81%, and the average quarterly price growth was -0.17%.

Reported Earning Dates

MASI is expected to report earnings on Aug 12, 2025.

PACB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+1.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MASI($7.66B) has a higher market cap than PACB($977M). MASI YTD gains are higher at: 1.373 vs. PACB (-12.568). MASI has higher annual earnings (EBITDA): 237M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. MASI (163M). PACB (934M) and MASI (970M) have identical debt. MASI has higher revenues than PACB: MASI (2.05B) vs PACB (201M).
MASIPACBMASI / PACB
Capitalization7.66B977M784%
EBITDA237M-277.28M-85%
Gain YTD1.373-12.568-11%
P/E Ratio95.93N/A-
Revenue2.05B201M1,019%
Total Cash163M631M26%
Total Debt970M934M104%
FUNDAMENTALS RATINGS
MASI vs PACB: Fundamental Ratings
MASI
PACB
OUTLOOK RATING
1..100
1743
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
4839
P/E GROWTH RATING
1..100
1780
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MASI's Valuation (90) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

MASI's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

MASI's SMR Rating (96) in the Medical Specialties industry is in the same range as PACB (99) in the Biotechnology industry. This means that MASI’s stock grew similarly to PACB’s over the last 12 months.

PACB's Price Growth Rating (39) in the Biotechnology industry is in the same range as MASI (48) in the Medical Specialties industry. This means that PACB’s stock grew similarly to MASI’s over the last 12 months.

MASI's P/E Growth Rating (17) in the Medical Specialties industry is somewhat better than the same rating for PACB (80) in the Biotechnology industry. This means that MASI’s stock grew somewhat faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MASIPACB
RSI
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
MASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COPLX198.211.67
+0.85%
Copley Fund
LMVFX122.910.49
+0.40%
ClearBridge Value FI
IGMIX10.340.04
+0.39%
Voya Global Insights Portfolio I
RERAX56.700.12
+0.21%
American Funds EUPAC R1
OBIOX23.00N/A
N/A
Oberweis International Opps Inv

MASI and

Correlation & Price change

A.I.dvisor indicates that over the last year, MASI has been loosely correlated with INSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MASI jumps, then INSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MASI
1D Price
Change %
MASI100%
-2.20%
INSP - MASI
47%
Loosely correlated
-1.71%
ISRG - MASI
46%
Loosely correlated
+1.20%
VCYT - MASI
44%
Loosely correlated
N/A
BSX - MASI
44%
Loosely correlated
-0.44%
ALGN - MASI
43%
Loosely correlated
-0.08%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+7.38%
MASI - PACB
58%
Loosely correlated
-2.20%
ILMN - PACB
47%
Loosely correlated
N/A
LAB - PACB
46%
Loosely correlated
-1.46%
AZTA - PACB
45%
Loosely correlated
+1.16%
BRKR - PACB
45%
Loosely correlated
-0.02%
More